Positions

Overview

  • Dr. Sudarshan received his undergraduate degree from Duke University, followed by his medical school training at the Duke University School of Medicine. He subsequently completed his residency in Urologic surgery at the Medical University of South Carolina. It was during his residency that he investigated gene therapy-based strategies for genitourinary malignancies. Dr. Sudarshan further pursued his interest in urologic oncology by completing a fellowship at the National Cancer Institute of the National Institutes of Health. During this fellowship, Dr. Sudarshan's clinical interests encompassed the utilization of minimally invasive approaches to the management of urologic cancers, including advanced laparoscopic techniques for renal/adrenal malignancy as well as robotic-assisted laparoscopic prostatectomy.
  • Research Overview

  • The Metabolic Basic of Kidney Cancer - Our laboratory’s principal focus has been to study the metabolic alterations of kidney cancer, also referred to as renal cell carcinoma (RCC). We study both rare hereditary forms of RCC as well as in sporadic kidney cancer. We are interested in hereditary forms of renal cancer as we believe the study of these disease variants can provide insight into more common, sporadic forms of this disease. We are interested in how metabolic remodeling contributes to tumor formation, progression, as well as response to therapy. In particular, our laboratory is interested in the connection between tumor metabolism and epigenetics. The overarching goal is to perform mechanistic studies that will advance our current knowledge base of kidney cancer in order to develop better methods to treat patients with advanced disease.

    Keywords - urologic oncology, scientific research understanding the molecular basis of renal cancer
  • Investigator On

  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Cancer Cell Biology Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2017 - 2020
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • UAB 1360: Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-Muscle-Invasive Transitional Cell Bladder Cancer  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2014 - 2019
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION 2015 - 2019
  • Private Grant  awarded by VIVENTIA BIO, INC. 2017 - 2018
  • Registry for Treatment of Upper Urinary Tract Tumours: A Multi-Center, International Registry to Evaluate the Treatment of Upper Tract Urothelial Cancer (UTUC): Incidence, Indications, Treatment types and Outcomes  awarded by THE ENDOUROLOGY SOCIETY 2016 - 2017
  • A Phase II Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract (PFE/PomX) in Subjects with Clinically Localized Prostate Cancer Undergoing Active Surveillance  awarded by University of Wisconsin-Madison 2013 - 2016
  • A Specific Screening Strategy to Reduce Prostate Cancer Mortality  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2012 - 2015
  • Private Grant  awarded by LEIDOS BIOMEDICAL RESEARCH, INC. 2013 - 2014
  • Tissue Resource Site (TSS) in Support of the The Cancer Genome Atlas (TCGA) Program - Admin Core  awarded by SAIC - FREDERICK 2013 - 2014
  • Education And Training

  • Doctor of Medicine, Duke University 1999
  • Medical University of South Carolina Medical Cente, Residency 2005
  • Medical University of South Carolina Medical Cente, Residency 2002
  • National Cancer Institute, Postdoctoral Fellowship 2007
  • Full Name

  • Sunil Sudarshan